USPTO serial 79328751
PHARMACT
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- May 2, 2023
- Examiner
- MESSICK, TABITHA LEE
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with PHARMACT?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
CH
CH
CH
DE
DE
DE
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Brian P. Gregg
Brian P. Gregg McNees Wallace & Nurick100 Pine StreetHarrisburg, PA 17108UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | medicines for human purposes for the treatment or prophylaxis of the nervous system, for treatment or prophylaxis of the endocrine system, for treatment or prophylaxis of cardiovascular system, injectable pharmaceutical for treatment or prophylaxis of respiratory tract, injectable pharmaceutical for treatment or prophylaxis of gastro intestinal tract, injectable pharmaceutical for treatment or prophylaxis of kidney or urinary tract, injectable pharmaceutical for treatment or prophylaxis of skin, injectable vitamins, injectable antibiotics, injectable synthetic chemotherapeutic agents, injectable antimyotics, injectable pharmaceuticals for treatment or prophylaxis of mycobacteria, injectable pharmaceuticals for treatment or prophylaxis of parasites, injectable pharmaceuticals for treatment or prophylaxis of virus infections, injectable cytokine agents, injectable disinfectant , injectable pharmaceuticals for treatment of malignant tumors, injectable pharmaceuticals for treatment of or prophylaxis of extracellular matrix, injectable pharmaceutical for treatment or prophylaxis of a hyaluronan-associated and proteoglycan-associated disease or disorder; pharmaceuticals, namely, injectable pharmaceutical for treatment or prophylaxis of homozygous familial hypercholesterolemia, of heterozygous familial hypercholesterolemia, of diabetic foot syndrome, of arterial hypertension or cardiac insufficiency; pharmaceuticals, namely, injectable pharmaceutical for treatment or prophylaxis of a neurodegenerative disease associated with an increased cerebral glycosaminoglycan level, injectable pharmaceutical for treatment or prophylaxis of Alzheimer's disease, of vascular dementia, of Parkinson's disease, of multiple sclerosis, of amyotrophic lateral sclerosis, of cerebral insult, of brain trauma, of cerebral inflammations, and of autoimmune encephalitis; pharmaceuticals, namely, injectable pharmaceutical for treatment or prophylaxis of radiation disease, injectable pharmaceutical for treatment or prophylaxis of tendovaginitis, of enthesiopathy, of insertion tendinosis, of insertion tendinopathy, of tendonitis, of periarthritis, of periathrosis, of arthrosis, of osteoarthrosis, of fibrosis, of renal fibrosis, of liver fibrosis, of cardiac fibrosis, of cardiac valve fibrosis, of pulmonary fibrosis, of pulmonary cirrhosis, of pulmonary sclerosis, of cerebral insult, of cerebral stroke, of apoplectic insult, of apoplexia cerebri, of ictus apoplecticus, of cerebral infarction, of brain scars, of gliosis,of contracture, of fibrotendinous contracture, of fibrous contracture, of joint contracture, of tendon contracture, of Dupuytren's contracture, of Dupuytren's disease, of Dupuytren's contracture, of glaucoma, of eye pressure elevation, of intraocular pressure elevation, of primary chronic glaucoma, of Multiple sclerosis, of disseminated demyelinating encephalomyelitis, of encephalomyelitis disseminata, of encephalitis disseminata, of cerebral polysclerosis, of amyotrophic lateral sclerosis, of myatrophic lateral sclerosis, of motoneuron disease, of Lou Gehrig's syndrome, of postcovid syndrome, of longcovid syndrome; cardiovascular agents for medical purposes; pharmaceutical preparations for treating hypertension; cardiovascular drugs used in angina pectoris, namely, drug delivery agents in the form of tablets, capsules, sprays, injections that provide controlled release of active ingredients for use in treating angina pectoris; cardiovascular drugs, namely, drug delivery agents in the form of tablets, capsules, sprays, injections, that provide controlled release of active ingredients for use in treating congestive heart failure; cardiovascular drugs, namely, drug delivery agents in the form of tablets, capsules, sprays, injections that provide controlled release of active ingredients for use in myocardial infarction; pharmaceutical preparations for the treatment of heart rhythm disorders; antiseptics; anti-inflammatory preparations; pharmaceuticals for the treatment of erectile dysfunction; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for the prevention of diabetes; pharmaceutical preparations for the treatment of parkinson's disease; pharmaceutical preparations for the treatment of kidney diseases; anti-cancer drugs, namely, pharmaceutical products for the prevention and treatment of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for use in ophthalmology; amino acid preparations for medical purposes; pharmaceutical preparations for treating hypoglycemia; pharmaceutical preparations for the treatment of osteoporosis; pharmaceutical preparations for activating cellular function; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical preparations for the treatment of musculo-skeletal disorders; ferments for medical or veterinary use; eye bandages for medical use; living cells for medical use; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; pharmaceutical preparations for treating asthma; pharmaceutical preparations for treating arthritis; pharmaceutical preparations for the treatment of hyperlipidemia; medicines for dental purposes; diagnostic preparations for medical or veterinary purposes; diagnostic agents for medical pharmaceutical use; biological indicators for medical diagnosis; diagnostic reagents for medical use; diagnostic biomarker reagents for medical purposes; clinical diagnostic reagents for medical use; in vitro diagnostic preparations for medical use; reagents for in-vitro laboratory use for medical purposes; immunoassay reagents for medical use; medical diagnostic test strips for detection of h-FABP being Heart-type Fatty Acid-Binding protein in the diagnosis of myocardial infarct, for detection of cTnI being Troponin I in the diagnosis of myocardial infarct, for detection of SARS-CoV-2 antigen in the diagnosis of Corona disease, for detection of proinsulin for diagnosis of humans with abnormal insulin secretion, for the detection of YKL-40 being CHI3L1 protein for diagnosis and treatment of liver fibrosis; test strips for measuring blood glucose levels; impregnated medicated swabs; wadding for medical purposes; swabs for medical use; cellulose wadding for medical purposes; tampons for medical purposes; reagent paper for medical or veterinary purposes; impregnated pre-moistened medicated wipes; mouthwashes for medical purposes | ACTIVE | — |
| 010 | Medical diagnostic apparatus for testing for viruses; medical apparatus for analysing bacteria in biological samples; medical instruments for infectious disease testing; medical diagnostic testing instruments for use in immunoassay procedure; genetic testing apparatus for medical purposes; medical devices for obtaining body fluid samples, namely, meters for body fluids; medical test kits for diabetes monitoring for home use; medical apparatus for diagnosing suspected heart attacks; apparatus for DNA and RNA testing for medical purposes; chromatographic instruments for medical use for detection of h-FABP being Heart-type Fatty Acid-Binding protein in the diagnosis of myocardial infarct, for detection of cTnI being Troponin I in the diagnosis of myocardial infarct, for detection of SARS-CoV-2 antigen in the diagnosis of Corona disease, for detection of proinsulin for diagnosis of humans with abnormal insulin secretion, for the detection of YKL-40 being CHI3L1 protein for diagnosis and treatment of liver fibrosis; diagnostic measuring apparatus for medical use for detection of h-FABP being Heart-type Fatty Acid-Binding protein in the diagnosis of myocardial infarct, for detection of cTnI being Troponin I in the diagnosis of myocardial infarct, for detection of SARS-CoV-2 antigen in the diagnosis of Corona disease, for detection of proinsulin for diagnosis of humans with abnormal insulin secretion, for the detection of YKL-40 being CHI3L1 protein for diagnosis and treatment of liver fibrosis; diagnostic apparatus for medical purposes, namely, ultrasound diagnostic apparatus, diagnostic apparatus for detection of cancer, diagnostic apparatus for detection of myocardial infarct, diagnostic apparatus for detection of cardiac rhythm disorder, diagnostic apparatus for detection of hypertension, diagnostic apparatus for detection of liver fibrosis, diagnostic apparatus for detection of hypercholesterolemia, diagnostic apparatus for detection of heterozygous familial hypercholesterolemia, diagnostic apparatus for detection of diabetic foot syndrome, diagnostic apparatus for detection of Alzheimer's disease, diagnostic apparatus for detection of vascular dementia, diagnostic apparatus for detection of Parkinson's disease, diagnostic apparatus for detection of multiple sclerosis, diagnostic apparatus for detection of amyotrophic lateral sclerosis, diagnostic apparatus for detection of cerebral insult, diagnostic apparatus for detection of brain trauma, diagnostic apparatus for detection of cerebral inflammations, and diagnostic apparatus for detection of autoimmune encephalitis; testing apparatus for medical purposes for testing blood sugar levels, for testing cancer cells, for testing DNA; protective face masks for medical use for anti bacterial protection; blood collection tubes for medical use; medical diagnostic saliva vials; temperature indicator labels for medical purposes; temperature measuring instruments for medical use in the nature of clinical thermometers; medical devices, namely, receptacles for applying medicines; patient monitoring instruments, namely, heart rate monitoring apparatus; containers especially made for medical waste; medical diagnostic testing instruments for use in immunoassay procedure; medical device, namely, immunoadsorption columns for therapeutic use; specimen cup holders; gamma cameras for medical purposes; light sources for medical use, namely, light emitting diode apparatus for lighting, incorporated into medical instruments; lancets; measuring devices for medical use in the nature of devices for measuring wounds, devices for measuring blood sugar for medical purposes; blood lancets; pipetting instruments in the nature of dropping pipettes for medical use; blood glucose testing apparatus; medical device, namely, immunoadsorption columns for diagnostic use; spittoons for medical purposes | ACTIVE | — |
| 042 | Pharmaceutical research and development; quality control for others; pharmaceutical product evaluation; consultancy pertaining to pharmacology; laboratory research services relating to pharmaceuticals | ACTIVE | — |
| 044 | Medical services; medical testing services relating to the diagnosis and treatment of disease; medical analysis for the diagnosis and treatment of persons; medical laboratory services for the analysis of samples taken from patients; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; medical analysis services relating to the treatment of animals provided by medical laboratory; medical treatment services of treating myocardial infarct, hypertension, liver fibrosis, hypercholesterolemia , heterozygous familial hypercholesterolemia, diabetic foot syndrome, Alzheimer's disease, vascular dementia, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis , cerebral insult, brain trauma, cerebral inflammations, and autoimmune encephalitis; medical testing for diagnostic or treatment purposes; medical services for the treatment of skin cancer; health care services for treating alzheimer's disease; medical analysis of human serum for medical treatment; providing information relating to the treatment of cardiovascular and cerebrovascular diseases via the internet; medical services relating to the removal, treatment and processing of human blood; medical services relating to the removal, treatment and processing of human cells; medical services in the nature of pharmacologicaltherapy services for treating myocardial infarct, hypertension, liver fibrosis, hypercholesterolemia , heterozygous familial hypercholesterolemia, diabetic foot syndrome, Alzheimer's disease, vascular dementia, Parkinson's disease, multiple sclerosis, amyotrophic lateral sclerosis,cerebral insult, brain trauma, cerebral inflammations, and autoimmune encephalitis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Pharmact Holding AG
- Other trademarks owned by Pharmact Holding AG
- Other trademarks owned by Pharmact Holding AG
- Other trademarks owned by Rainer Böhnke
- Other trademarks owned by Rainer Böhnke
- Other trademarks owned by Rainer Böhnke
- Other trademarks in Class 005
- Other trademarks in Class 010
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named PHARMACT
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 3, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Aug 8, 2023 | XXSS | GENERIC MADRID TRANSACTION SENT TO IB | — |
| Aug 8, 2023 | XXCR | GENERIC MADRID TRANSACTION CREATED | — |
| Aug 2, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| May 2, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| May 2, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Feb 14, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Feb 14, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Feb 14, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 25, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 25, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Jan 25, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jan 12, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jan 12, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jan 12, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jan 12, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jan 12, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 2, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 2, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 2, 2023 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 26, 2022 | RFNP | REFUSAL PROCESSED BY IB | — |
| Jul 7, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Jul 6, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Jul 6, 2022 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Jun 19, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Jun 18, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 9, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 5, 2022 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Mar 17, 2022 | CORR | CORRECTION FROM IB ENTERED - NO REVIEW REQUIRED | — |
| Feb 19, 2022 | CRCV | CORRECTION TRANSACTION RECEIVED FROM IB | — |
| Dec 22, 2021 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Dec 18, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Dec 16, 2021 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |